{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T17:31:41Z","timestamp":1790098301800,"version":"4.0.1"},"reference-count":34,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,9,28]],"date-time":"2022-09-28T00:00:00Z","timestamp":1664323200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:p>Infantile-onset Pompe disease (IOPD) is a rare, severe disorder of lysosomal storage of glycogen that leads to progressive cardiac and skeletal myopathy. IOPD is a fatal disease in childhood unless treated with enzyme replacement therapy (ERT) from an early age. Sickle cell anemia (SCA) is a relatively common hemoglobinopathy caused by a specific variant in the hemoglobin beta-chain. Here we report a case of a male newborn of African ancestry diagnosed and treated for IOPD and SCA. Molecular testing confirmed two <jats:italic>GAA<\/jats:italic> variants, NM_000152.5: c.842G&amp;gt;C, p.(Arg281Pro) and NM_000152.5: c.2560C&amp;gt;T, p.(Arg854<jats:sup>*<\/jats:sup>) in <jats:italic>trans<\/jats:italic>, and homozygosity for the <jats:italic>HBB<\/jats:italic> variant causative of SCA, consistent with his diagnosis. An acute neonatal presentation of hypotonia and cardiomyopathy required ERT with alglucosidase alfa infusions preceded by immune tolerance induction (ITI), as well as chronic red blood cell transfusions and penicillin V potassium prophylaxis for treatment of IOPD and SCA. Clinical course was further complicated by multiple respiratory infections. We review the current guidelines and interventions taken to optimize his care and the pitfalls of those guidelines when treating patients with concomitant conditions. To the best of our knowledge, no other case reports of the concomitance of these two disorders was found. This report emphasizes the importance of newborn screening, early intervention, and treatment considerations for this complex patient presentation of IOPD and SCA.<\/jats:p>","DOI":"10.3389\/fped.2022.944178","type":"journal-article","created":{"date-parts":[[2022,9,28]],"date-time":"2022-09-28T14:29:14Z","timestamp":1664375354000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Infantile-onset Pompe disease complicated by sickle cell anemia: Case report and management considerations"],"prefix":"10.3389","volume":"10","author":[{"given":"Rodrigo Tzovenos","family":"Starosta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying-Chen Claire","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katelyn","family":"Leestma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prapti","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luke","family":"Viehl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Manwaring","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge Luis","family":"Granadillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Molly C.","family":"Schroeder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie N.","family":"Colombo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Halana","family":"Whitehead","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia Irene","family":"Dickson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica L.","family":"Hulbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hoanh Thi","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,9,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/j.jpeds.2005.11.033","article-title":"A retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease","volume":"148","author":"Kishnani","year":"2006","journal-title":"J Pediatr."},{"key":"B2","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.jpeds.2019.08.058","article-title":"Clinical and molecular disease spectrum and outcomes in patients with infantile-onset pompe disease","volume":"216","author":"Gupta","year":"2020","journal-title":"J Pediatr."},{"key":"B3","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.ymgme.2016.12.004","article-title":"The emerging phenotype of late-onset Pompe disease: a systematic literature review","volume":"120","author":"Chan","year":"2017","journal-title":"Mol Genet Metab."},{"key":"B4","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1212\/01.wnl.0000251268.41188.04","article-title":"Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease","volume":"68","author":"Kishnani","year":"2007","journal-title":"Neurology."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1002\/jimd.12268","article-title":"Effects of higher and more frequent dosing of alglucosidase alfa and immunomodulation on long-term clinical outcome of classic infantile Pompe patients","volume":"43","author":"Poelman","year":"2020","journal-title":"J Inherit Metab Dis."},{"key":"B6","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1007\/s10545-015-9912-y","article-title":"Effects of a higher dose of alglucosidase alfa on ventilator-free survival and motor outcome in classic infantile Pompe disease: an open-label single-center study","volume":"39","author":"van Gelder","year":"2016","journal-title":"J Inherit Metab Dis."},{"key":"B7","doi-asserted-by":"publisher","first-page":"11","DOI":"10.3390\/children8111026","article-title":"Importance of timely treatment initiation in infantile-onset pompe disease, a single-centre experience","volume":"8","author":"de Las Heras","year":"2021","journal-title":"Children (Basel)."},{"key":"B8","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1097\/GIM.0b013e3182174703","article-title":"The impact of antibodies on clinical outcomes in diseases treated with therapeutic protein: lessons learned from infantile Pompe disease","volume":"13","author":"Banugaria","year":"2011","journal-title":"Genet Med."},{"key":"B9","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1038\/s41436-020-01080-y","article-title":"Transforming the clinical outcome in CRIM-negative infantile Pompe disease identified via newborn screening: the benefits of early treatment with enzyme replacement therapy and immune tolerance induction","volume":"23","author":"Li","year":"2021","journal-title":"Genet Med."},{"key":"B10","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1038\/s41436-018-0270-7","article-title":"An immune tolerance approach using transient low-dose methotrexate in the ERT-na\u00efve setting of patients treated with a therapeutic protein: experience in infantile-onset Pompe disease","volume":"21","author":"Kazi","year":"2019","journal-title":"Genet Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1002\/ajh.10154","article-title":"Cardiac abnormalities in children with sickle cell anemia","volume":"70","author":"Batra","year":"2002","journal-title":"Am J Hematol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1016\/j.jacc.2011.10.900","article-title":"Cardiovascular abnormalities in sickle cell disease","volume":"59","author":"Gladwin","year":"2012","journal-title":"J Am Coll Cardiol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.bcmd.2017.03.015","article-title":"Cerebral and muscle microvascular oxygenation in children with sickle cell disease: Influence of hematology, hemorheology and vasomotion","volume":"65","author":"Charlot","year":"2017","journal-title":"Blood Cells Mol Dis."},{"key":"B14","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s12687-012-0118-9","article-title":"Screening criteria: the need to deal with new developments and ethical issues in newborn metabolic screening","volume":"4","author":"Forman","year":"2013","journal-title":"J Community Genet."},{"key":"B15","doi-asserted-by":"publisher","first-page":"72","DOI":"10.3390\/ijns6030072","article-title":"Current Practices for U.S. Newborn Screening of Pompe Disease and MPSI","volume":"6","author":"Ames","year":"2020","journal-title":"Int J Neonatal Screen."},{"key":"B16","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1002\/(SICI)1096-8628(19980827)79:1<69::AID-AJMG16>3.0.CO;2-K","article-title":"Carrier frequency for glycogen storage disease type II in New York and estimates of affected individuals born with the disease","volume":"79","author":"Martiniuk","year":"1998","journal-title":"Am J Med Genet."},{"key":"B17","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1002\/jmd2.12201","article-title":"Selective screening for lysosomal storage disorders in a large cohort of minorities of African descent shows high prevalence rates and novel variants","volume":"59","author":"Limgala","year":"2021","journal-title":"JIMD Rep."},{"key":"B18","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.ymgme.2021.09.001","article-title":"Health care practitioners' experience-based opinions on providing care after a positive newborn screen for Pompe disease","volume":"134","author":"Davids","year":"2021","journal-title":"Mol Genet Metab."},{"key":"B19","author":"Sedrak","year":"2022","journal-title":"StatPearls"},{"key":"B20","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1002\/humu.10286","article-title":"Twenty-two novel mutations in the lysosomal alpha-glucosidase gene (GAA) underscore the genotype-phenotype correlation in glycogen storage disease type II","volume":"23","author":"Hermans","year":"2004","journal-title":"Hum Mutat."},{"key":"B21","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/j.ymgme.2011.08.003","article-title":"Atypical immunologic response in a patient with CRIM-negative Pompe disease","volume":"104","author":"Abbott","year":"2011","journal-title":"Mol Genet Metab."},{"key":"B22","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1002\/ajmg.c.31319","article-title":"Predicting cross-reactive immunological material (CRIM) status in Pompe disease using GAA mutations: lessons learned from 10 years of clinical laboratory testing experience","author":"Bali","year":"2012","journal-title":"Am J Med Genet C Semin Med Genet."},{"key":"B23","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1042\/bj2890687","article-title":"The conservative substitution Asp-645\u2013>Glu in lysosomal alpha-glucosidase affects transport and phosphorylation of the enzyme in an adult patient with glycogen-storage disease type II","volume":"289","author":"Hermans","year":"1993","journal-title":"Biochem J."},{"key":"B24","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1086\/301788","article-title":"The African origin of the common mutation in African American patients with glycogen-storage disease type II","volume":"62","author":"Becker","year":"1998","journal-title":"Am J Hum Genet."},{"key":"B25","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1002\/ajmg.c.31318","article-title":"The genotype-phenotype correlation in Pompe disease","author":"Kroos","year":"2012","journal-title":"Am J Med Genet C Semin Med Genet."},{"key":"B26","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/gim.2015.30","article-title":"Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American college of medical genetics and genomics and the association for molecular pathology","volume":"17","author":"Richards","year":"2015","journal-title":"Genet Med."},{"key":"B27","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/8904_2012_130","article-title":"Newborn screening for lysosomal storage disorders in Hungary","volume":"6","author":"Wittmann","year":"2012","journal-title":"JIMD Rep."},{"key":"B28","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1097\/GIM.0b013e31819d0996","article-title":"Clinical outcomes after long-term treatment with alglucosidase alfa in infants and children with advanced Pompe disease","volume":"11","author":"Nicolino","year":"2009","journal-title":"Genet Med."},{"key":"B29","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1016\/j.jpeds.2014.10.068","article-title":"Long-term prognosis of patients with infantile-onset Pompe disease diagnosed by newborn screening and treated since birth","volume":"166","author":"Chien","year":"2015","journal-title":"J Pediatr."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.3389\/fimmu.2020.01727","article-title":"Benefits of prophylactic short-course immune tolerance induction in patients with infantile pompe disease: demonstration of long-term safety and efficacy in an expanded cohort","volume":"11","author":"Desai","year":"2020","journal-title":"Front Immunol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"100475","DOI":"10.1016\/j.ymgmr.2019.100475","article-title":"Characterization of immune response in cross-reactive immunological material (CRIM)-positive infantile pompe disease patients treated with enzyme replacement therapy","volume":"20","author":"Desai","year":"2019","journal-title":"Mol Genet Metab Rep."},{"key":"B32","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s40164-017-0078-1","article-title":"Low-dose methotrexate in sickle-cell disease: a pilot study with rationale borrowed from rheumatoid arthritis","volume":"6","author":"Brandalise","year":"2017","journal-title":"Exp Hematol Oncol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"3925","DOI":"10.1182\/blood-2011-11-392340","article-title":"Stroke with transfusions changing to hydroxyurea (SWiTCH)","volume":"119","author":"Ware","year":"2012","journal-title":"Blood."},{"key":"B34","doi-asserted-by":"publisher","first-page":"3027","DOI":"10.1111\/trf.16640","article-title":"The transfusion management of beta thalassemia in the United States","volume":"61","author":"Lal","year":"2021","journal-title":"Transfusion."}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2022.944178\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,28]],"date-time":"2022-09-28T14:29:18Z","timestamp":1664375358000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2022.944178\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,28]]},"references-count":34,"alternative-id":["10.3389\/fped.2022.944178"],"URL":"https:\/\/doi.org\/10.3389\/fped.2022.944178","relation":{},"ISSN":["2296-2360"],"issn-type":[{"value":"2296-2360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,28]]},"article-number":"944178"}}